Hormone replacement therapy has been proven efficacious for controlling vasomotor symptoms such as hot flushes associated with menopause. Drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity that may be used in combination with estrogen to control hot flushes and offers the potential benefit of minimizing breast tenderness, blood pressure elevations and weight gain. Six clinical trials were reviewed. Of these, four trials explicitly listed hot flushes as a primary outcome. Efficacy with regards to hot flushes was found to range from modest to large ( i.e., 37.5% to 94.6%), and four of the studies utilized diary cards to assess hot flushes. Results from these studies must be interpreted cautiously as quite a few limitations existed such as small population sizes involving specific ethnic groups, lack of p values with regards to baseline characteristics lending question to homogeneity, and inclusion of mostly healthy participants. Additionally, while the studies were long enough to see an effect, the long term effects of drospirenone-containing hormone replacement therapy (HRT) is unknown. The available data supports the use of drospirenone-containing HRT for the treatment of hot flushes associated with menopause.
References
[1]
Utian, W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual. Life Outcomes 2005, 3, doi:10.1186/1477-7525-3-47.
[2]
Sturdee, D.W.; Panay, N. Recommendation for the management of postmenopausal vaginal atrophy. Climacteric 2010, 13, 509–522.
[3]
Pines, A.; Sturdee, D.W.; Birkh？user, M.H.; Schneider, H.P.; Gambacciani, M.; Panay, N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007, 10, 181–194.
[4]
Carranza-Lira, S. Safety, efficacy and patient acceptability of drospiranone and estradiol in the treatment of menopausal vasomotor symptoms: A review. Clin. Interv. Aging 2009, 4, 59–62.
[5]
Yikorkala, O. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Climacteric 2005, 8, 1–3.
[6]
Oelkers, W. Drospirenone, a progestogen with antimieralocorticoid properties: A short review. Mol. Cell. Endocrinol. 2004, 217, 255–261.
[7]
Angeliq？ (package insert). Available online: http://berlex.bayerhealthcare.com/html/products/pi/fhc/Angeliq_PI.pdf (accessed on 28 June 2013).
[8]
Lee, B.S.; Kang, B.M.; Yoon, B.K.; Choi, H.; Park, H.M.; Kim, J.G. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study. Maturitas 2007, 57, 361–369.
[9]
Schurmann, R.; Holler, T.; Benda, N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: A double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004, 7, 189–196.
[10]
Gambacciani, M.; Rosano, G.; Cappagli, B.; Pepe, A.; Vitale, C.; Genazzani, A.R. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: A prospective study. Climacteric 2011, 14, 18–24.
[11]
Chaikittisilpa, S.; Angsuwathana, S.; Chaovisitsaree, S.; Jirapinyo, M.; Wilawan, K.; Panyakhamlerd, K.; Jaisamrarn, U.; Techatraisak, K.; Morakote, N.; Suchartwatnachai, C.; et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J. Med. Assoc. Thai. 2011, 94, 1019–1025.
[12]
Lin, S.Q.; Sun, L.Z.; Lin, J.F.; Yang, X.; Zhang, L.J.; Qiao, J.; Wang, Z.H.; Xu, Y.X.; Xiong, Z.A.; Zhou, Y.Z.; et al. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric 2011, 14, 472–481.
[13]
Archer, D.F.; Thorneycroft, I.H.; Foegh, M.; Hanes, V.; Glant, M.D.; Bitterman, P.; Kempson, R.L. Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial. Menopause 2005, 12, 716–727.
[14]
Dinger, J.C.; Heinemann, L.A.J.; Kuhl-Habich, D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance study on oral contraceptives based on 142, 475 women-years of observation. Contraception 2007, 75, 344–354.
[15]
Lidegaard, O.; Nielsen, L.H.; Skovlund, C.W.; Skjeldestad, F.E.; Lokkegaard, E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. Br. Med. J. 2011, doi:10.1136/bmj.d6423.
